A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation

Sulforaphane (SFN), a naturally occurring isothiocyanate found in cruciferous vegetables, is implicated as a possible therapy for airway inflammation via induction of the transcription factor NF-E2-related factor 2 (NRF2). In this proof-of-concept clinical study, we show that supplementation of SFN...

Descripción completa

Detalles Bibliográficos
Autores principales: Duran, Charity G., Burbank, Allison J., Mills, Katherine H., Duckworth, Heather R., Aleman, Maria M., Kesic, Matthew J., Peden, David B., Pan, Yinghao, Zhou, Haibo, Hernandez, Michelle L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957339/
https://www.ncbi.nlm.nih.gov/pubmed/27450419
http://dx.doi.org/10.1186/s12931-016-0406-8
_version_ 1782444164385865728
author Duran, Charity G.
Burbank, Allison J.
Mills, Katherine H.
Duckworth, Heather R.
Aleman, Maria M.
Kesic, Matthew J.
Peden, David B.
Pan, Yinghao
Zhou, Haibo
Hernandez, Michelle L.
author_facet Duran, Charity G.
Burbank, Allison J.
Mills, Katherine H.
Duckworth, Heather R.
Aleman, Maria M.
Kesic, Matthew J.
Peden, David B.
Pan, Yinghao
Zhou, Haibo
Hernandez, Michelle L.
author_sort Duran, Charity G.
collection PubMed
description Sulforaphane (SFN), a naturally occurring isothiocyanate found in cruciferous vegetables, is implicated as a possible therapy for airway inflammation via induction of the transcription factor NF-E2-related factor 2 (NRF2). In this proof-of-concept clinical study, we show that supplementation of SFN with broccoli sprout homogenate in healthy human subjects did not induce expression of antioxidant genes or protect against neutrophilic airway inflammation in an ozone-exposure model. Therefore, dietary sulforaphane supplementation is not a promising candidate for larger scale clinical trials targeting airway inflammation. Trial registration:NCT01625130. Registered 19 June, 2012.
format Online
Article
Text
id pubmed-4957339
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49573392016-07-23 A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation Duran, Charity G. Burbank, Allison J. Mills, Katherine H. Duckworth, Heather R. Aleman, Maria M. Kesic, Matthew J. Peden, David B. Pan, Yinghao Zhou, Haibo Hernandez, Michelle L. Respir Res Letter to the Editor Sulforaphane (SFN), a naturally occurring isothiocyanate found in cruciferous vegetables, is implicated as a possible therapy for airway inflammation via induction of the transcription factor NF-E2-related factor 2 (NRF2). In this proof-of-concept clinical study, we show that supplementation of SFN with broccoli sprout homogenate in healthy human subjects did not induce expression of antioxidant genes or protect against neutrophilic airway inflammation in an ozone-exposure model. Therefore, dietary sulforaphane supplementation is not a promising candidate for larger scale clinical trials targeting airway inflammation. Trial registration:NCT01625130. Registered 19 June, 2012. BioMed Central 2016-07-22 2016 /pmc/articles/PMC4957339/ /pubmed/27450419 http://dx.doi.org/10.1186/s12931-016-0406-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Duran, Charity G.
Burbank, Allison J.
Mills, Katherine H.
Duckworth, Heather R.
Aleman, Maria M.
Kesic, Matthew J.
Peden, David B.
Pan, Yinghao
Zhou, Haibo
Hernandez, Michelle L.
A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation
title A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation
title_full A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation
title_fullStr A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation
title_full_unstemmed A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation
title_short A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation
title_sort proof-of-concept clinical study examining the nrf2 activator sulforaphane against neutrophilic airway inflammation
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957339/
https://www.ncbi.nlm.nih.gov/pubmed/27450419
http://dx.doi.org/10.1186/s12931-016-0406-8
work_keys_str_mv AT durancharityg aproofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT burbankallisonj aproofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT millskatherineh aproofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT duckworthheatherr aproofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT alemanmariam aproofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT kesicmatthewj aproofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT pedendavidb aproofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT panyinghao aproofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT zhouhaibo aproofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT hernandezmichellel aproofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT durancharityg proofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT burbankallisonj proofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT millskatherineh proofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT duckworthheatherr proofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT alemanmariam proofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT kesicmatthewj proofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT pedendavidb proofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT panyinghao proofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT zhouhaibo proofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation
AT hernandezmichellel proofofconceptclinicalstudyexaminingthenrf2activatorsulforaphaneagainstneutrophilicairwayinflammation

Ejemplares similares